Amendments To The Claims

1-6. (canceled)

7. (currently amended) A compound selected from the following formulae (C1) to (C11) and (C13)-(C20) or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof:

C1)



C2)



C3)



C4)



C5)



C6)



,

C7)



,

C8)



C9)



,

C10)



,

C11)



,

C13)



,

C14)



C-15)



C16)



C17)



C18)



C19)



C20)



8. (currently amended) A compound represented by the structural formula AA



(AA)

or a pharmaceutically acceptable salt ~~or prodrug~~ thereof.

9. (currently amended) A compound selected from the group consisting of:







,



,



,



,



,



,



,





,



, and



; or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof.

10. (canceled)

11. (currently amended) ~~An ester derivative of the~~ A compound according to ~~of~~ claim 36 wherein Z_P includes a carboxyl group funcionalized as ~~a~~ selected from ~~a methyl ester, ethyl ester,~~ N,N-diethylglycolamido ester, or morpholinylethyl ester.

12. (previously presented) The salt derivative of the compound of claim 36 wherein the salt is sodium or potassium.

13. (previously presented) A pharmaceutical formulation comprising the compound of claim 36 either with a pharmaceutically acceptable carrier or diluent.

14. (withdrawn) A formulation for treating osteoporosis comprising:

Ingredient (A1): the vitamin D receptor modulator of claim 36 or;

Ingredient (B1):

one or more co-agents selected from the group consisting of:

a. estrogens,
b. androgens,
c. calcium supplements,
d. vitamin D metabolites,
e. thiazide diuretics,
f. calcitonin,
g. bisphosphonates,
h. SERMS, and
i. fluorides; and

Ingredient (C1): optionally, a carrier or diluent.

15. (withdrawn) The formulation of claim 14 wherein the weight ratio of (A1) to (B1) is from 10:1 to 1:1000.

16. (withdrawn) A formulation for treating psoriais comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 36;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

a. topical glucocorticoids ,
b. salicylic acid,
c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

17. (withdrawn) The formulation of claim 16 wherein the weight ratio of (A2) to (B2) is from 1:10 to 1:100000.

18. (withdrawn) A method of treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Insufficient sebum secretion,Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, Psoriasis, Scleroderma, Skin cancer, Skin cell damage from, Mustard vesicants,Wrinkles or Seborrheic dermatitis; wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to claim 36.

19. (withdrawn) The method of claim 18 for the treatment of psoriasis.

20. (withdrawn) The method of claim 18 for the treatment of osteoporosis.

21-22. (canceled)

23. (withdrawn, currently amended) A method of treating ~~or preventing~~ disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound according to claim 36.

24-35. (canceled)

36. (currently amended) A compound represented by a formula below:



wherein

R and R' are independently C_1-C_5 alkyl, ~~C_1-C_5 fluoroalkyl,~~ or together R and R' form a ~~substituted or unsubstituted,~~ saturated ~~or unsaturated~~ carbocyclic ring having from 3 to 8 carbon atoms;

RP_3 is ~~selected from~~ hydrogen~~, halo,~~ or C_1-C_5 alkyl~~, C_1-C_5 fluoroalkyl, O-C_1-C_5 alkyl, S-C_1-C_5 alkyl, O-C_1-C_5 fluoroalkyl, CN, NO_2, acetyl, S-C_1-C_5 fluoroalkyl, C_2-C_5 alkenyl, C_2-C_5 cycloalkyl, or C_2-C_5 cycloalkenyl;~~

(L_{P2}) is ~~a divalent linking group independently selected from:~~

~~a bond~~ ,



,

or



,

,

,



,

,~~-and~~



,

where m is 0, 1, or 2, ~~and each R40 is independently hydrogen, C_1-C_5 alkyl, or C_1-C_5 fluoroalkyl;~~

Z_P is a

branched C_3-C_5 alkyl~~;~~

~~1-hydroxycyclopentenyl;~~

~~1-hydroxycyclohexenyl;~~

~~1-hydroxycycloheptenyl,~~

~~1-hydroxycyclooctenyl,~~

~~1-hydroxycyclopropyl,~~

~~1-hydroxycyclobutyl,~~

~~1-hydroxycyclopentyl,~~

~~1-hydroxycyclohexyl,~~

~~2-oxocyclohexyloxy~~

~~2-oxocyclohexylmethyl~~

~~3-methyl-2-oxocyclohexyloxy~~

~~3-methyl-2-oxocyclohexylmethyl~~

~~3,3-dimethyl-2-oxocyclohexyloxy~~

~~3,3-dimethyl-2-oxocyclohexylmethyl~~

~~2-hydroxycyclohexyloxy~~

~~2-hydroxycyclohexylmethyl~~

~~3-methyl-2-hydroxycyclohexyloxy~~

~~3-methyl-2-hydroxycyclohexylmethyl~~

~~3,3-dimethyl-2-hydroxycyclohexyloxy~~

~~3,3-dimethyl-2-hydroxycyclohexylmethyl~~

~~1-hydroxycycloheptyl, or~~

~~1-hydroxycyclooctyl;~~

Z_{FB} is attached to the 5 or 6 position on the benzofuranyl ring and selected from:

$-CO_2H$

$-CO_2(C_1\text{-}C_5$ alkyl),

~~$-C(O)NMe_2$,~~

~~$-CO_2(C_2\text{-}C_5$ alkenyl),~~

~~$-CO_2(C_3\text{-}C_5$ cycloalkyl),~~

~~$-CO_2(C_3\text{-}C_5$ cycloalkenyl),~~

~~$-CO_2(C_1\text{-}C_5$ hydroxyalkyl),~~

~~$-CO_2(C_1\text{-}C_5$ fluoroalkyl),~~

~~$-CO_2(C_1\text{-}C_5$ alkyl) phenyl,~~

~~$-CO_2(C_1\text{-}C_5$ alkyl)-(O)-$(C_1\text{-}C_5$ alkyl),~~

$-CO_2(C_1\text{-}C_5$ alkyl)-NH_2,

~~$CO_2(C_1$-C_5-alkyl)-NH-(C_1-C_5-alkyl)$_2$,~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-NH_2,~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-NH-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-N-(C_1-C_5-alkyl)$_2$,~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-OH,~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-NH-5-tetrazolyl,~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-C(O)-(O-C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-NH_2,~~

~~$CO_2(C_1$-C_5-alkyl)-NH-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-N-(C_1-C_5-alkyl)$_2$,~~

~~$CO_2(C_1$-C_5-alkyl)-NH-SO_2-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-N-pyrrolidin-2-one,~~

~~$CO_2(C_1$-C_5-alkyl)-N-pyrrolidine,~~

~~$CO_2(C_1$-C_5-alkyl)-(1-methylpyrrolidin-2-one-3-yl),~~

~~$CO_2(C_1$-C_5-alkyl)-SO_2-(C_1-C_5-alkyl,)~~

~~$CO_2(C_1$-C_5-alkyl)-SO_2-NH_2,~~

~~$CO_2(C_1$-C_5-alkyl)-SO_2-NH-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-SO_2-N-(C_1-C_5-alkyl)$_2$,~~

~~$CO_2(C_1$-C_5-alkyl)-SO_2-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-S(O)-(C_1-C_5-alkyl,)~~

~~$CO_2(C_1$-C_5-alkyl)-S(O)-NH_2,~~

~~$CO_2(C_1$-C_5-alkyl)-S(O)-NH-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-S(O)-N-(C_1-C_5-alkyl)$_2$,~~

~~$CO_2(C_1$-C_5-alkyl)-S(O)-(C_1-C_5-alkyl),~~

~~$CO_2(C_1$-C_5-alkyl)-P(O)-(O-C_1-C_5-alkyl)$_2$,~~

~~$CO_2(C_1$-C_5-alkyl)-5-tetrazolyl,~~

~~CO_2CH_2-CO_2H,~~

~~CO_2CH_2-5-tetrazolyl,~~

~~$CO_2(C_1$-C_5 alkyl),~~

~~$CO_2C(O)$-NH_2,~~

~~$CO_2C(O)$-N-$(CH_3)_2$,~~

~~$CO_2C(S)$-N-$(CH_3)_2$;~~

~~$CO_2C(O)$-O-$(C_1$-C_5 alkyl),~~

~~CO_2(5-tetrazolyl),~~

~~CO_2SO_2-$(C_1$-C_5-alkyl,)~~

~~CO_2SO_2-NH_2,~~

~~CO_2SO_2-NH-$(C_1$-C_5-alkyl),~~

~~CO_2SO_2-N-$(C_1$-C_5-alkyl)$_2$,~~

~~$CO_2S(O)$-$(C_1$-C_5-alkyl,)~~

~~$CO_2S(O)$-NH_2,~~

~~$CO_2S(O)$-NH-$(C_1$-C_5-alkyl),~~

~~$CO_2S(O)$-N-$(C_1$-C_5-alkyl)$_2$,~~

-C(O)NH-CH_2-C(O)OH,

-C(O)NH-CH_2-C(O)OMe,

-C(O)NH-CH_2-C(O)OEt,

-C(O)NH-CH_2-C(O)OiPr,

-C(O)NH-CH_2-C(O)OtBu,

-C(O)NH-CH(Me)-C(O)OH,

-C(O)NH-CH(Me)-C(O)OMe,

-C(O)NH-CH(Me)-C(O)OEt,

-C(O)NH-CH(Me)-C(O)iPr,

-C(O)NH-CH(Me)-C(O)tBu,

-C(O)NH-CH(Et)-C(O)OH,

-C(O)NH-$C(Me)_2$-C(O)OH,

-C(O)NH-$C(Me)_2$-C(O)OMe,

-C(O)NH-$C(Me)_2$-C(O)OEt,

-C(O)NH-$C(Me)_2$-C(O)iPr,

-C(O)NH-$C(Me)_2$-C(O)tBu,

-C(O)NH-CMe(Et)-C(O)OH,

~~C(O)NH-CH(F)-C(O)OH,~~

~~-C(O)NH-CH(CF$_3$)-C(O)OH,~~

~~-C(O)NH-CH(OH)-C(O)OH,~~

~~-C(O)NH-CH(cyclopropyl)-C(O)OH,~~

~~-C(O)NH-C(Me)$_2$-C(O)OH,~~

~~-C(O)NH-C(Me)$_2$-C(O)OH,~~

~~-C(O)NH-CF(Me)-C(O)OH,~~

~~-C(O)NH-C(Me)(CF$_3$)-C(O)OH,~~

~~-C(O)NH-C(Me)(OH)-C(O)OH,~~

~~-C(O)NH-C(Me)(cyclopropyl)CO$_2$H~~

-C(O)NMe-CH$_2$-C(O)OH,

-C(O)NMe-CH$_2$-C(O)OMe,

-C(O)NMe-CH$_2$-C(O)OEt,

-C(O)NMe-CH$_2$-C(O)OiPr,

-C(O)NMe-CH$_2$-C(O)tBu,

~~-C(O)NMe-CH$_2$-C(O)OH,~~

-C(O)NMe-CH(Me)-C(O)OH,

~~-C(O)NMe-CH(F)-C(O)OH,~~

~~-C(O)NMe-CH(CF$_3$)-C(O)OH,~~

~~-C(O)NMe-CH(OH)-C(O)OH,~~

~~-C(O)NMe-CH(cyclopropyl)-C(O)OH,~~

~~-C(O)NMe-C(Me)$_2$-C(O)OH,~~

~~-C(O)NMe-CF(Me)-C(O)OH,~~

~~-C(O)NMe-C(Me)(CF$_3$)-C(O)OH,~~

~~-C(O)NMe-C(Me)(OH)-C(O)OH,~~

~~-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH,~~

~~-C(O)NHS(O)$_2$Me,~~

~~-C(O)NHSO$_2$Me,~~

-C(O)-NH-5-tetrazolyl,

-O-SO$_2$-C$_1$-C$_5$ alkyl),

-SO$_2$(C$_1$-C$_5$ alkyl),

CH$_2$S(O)$_2$Me,

CH$_2$S(O)$_2$Et, and

CH$_2$S(O)$_2$iPr,

~~C(O)NHS(O)Me,~~

~~C(O)NHS(O)Et,~~

~~C(O)NHSO$_2$Me,~~

~~C(O)NHSO$_2$Et,~~

~~C(O)NHS(O)iPr,~~

~~C(O)NHSO$_2$iPr,~~

~~C(O)NHS(O)tBu,~~

~~C(O)NHSO$_2$tBu,~~

~~C(O)NHCH$_2$S(O)Me,~~

~~C(O)NHCH$_2$S(O)Et,~~

~~C(O)NHCH$_2$SO$_2$Me,~~

~~C(O)NHCH$_2$SO$_2$Et,~~

~~C(O)NHCH$_2$CH$_2$S(O)Me,~~

~~C(O)NHCH$_2$CH$_2$S(O)Et,~~

~~C(O)NHCH$_2$CH$_2$SO$_2$Me,~~

~~C(O)NHCH$_2$CH$_2$SO$_2$Et,~~

~~C(O)N(Me)S(O)Me,~~

~~C(O)N(Me)SO$_2$Me,~~

~~C(O) N(Me) 5-tetrazolyl,~~

~~C(O)N(Me)S(O)Me,~~

~~C(O)N(Me)S(O)Et,~~

~~C(O)N(Me)SO$_2$Me,~~

~~C(O)N(Me)SO$_2$Et,~~

~~C(O)N(Me)S(O)iPr,~~

~~C(O)N(Me))SO$_2$iPr,~~

~~C(O)N(Me)S(O)tBu,~~

~~C(O)N(Me)SO$_2$tBu,~~

~~C(O)N(Me)CH$_2$S(O)Me,~~

~~C(O)N(Me)CH$_2$S(O)Et,~~

~~C(O)N(Me)CH$_2$SO$_2$Me,~~

~~$C(O)N(Me)CH_2SO_2Et$,~~

~~$C(O)N(Me)CH_2CH_2S(O)Me$,~~

~~$C(O)N(Me)CH_2CH_2S(O)Et$,~~

~~$C(O)N(Me)CH_2CH_2SO_2Me$, and~~

~~$C(O)N(Me)CH_2CH_2SO_2Et$;~~

and a pharmaceutically acceptable salt ~~or prodrug~~ thereof.

37. (previously presented) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

38. (previously presented) A compound represented by a formula:



,

and pharmaceutically acceptable salts thereof.

39. (withdrawn) A method of treating a mammal or alleviating the pathological effects of psoriasis, scleroderma, seborrheic dermatitis or skin cancer or, a mammal in need thereof comprising administered a pharmaceutically effective amount of a compound of Claim 37, or a pharmaceutically acceptable salt thereof.

40 (new) A compound represented by a formula:



,

and pharmaceutically acceptable salts thereof.

41. (new) A pharmaceutical formulation comprising the compound of claim 37 with a pharmaceutically acceptable carrier or diluent.

42. (new) A pharmaceutical formulation comprising the compound of claim 38 with a pharmaceutically acceptable carrier or diluent.

43. (new) A pharmaceutical formulation comprising the compound of claim 40 with a pharmaceutically acceptable carrier or diluent.